We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $633M
1-Year Est. Return 173.22%
This Fund
S&P 500
This Quarter Est. Return
-8.08%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$282M
AUM Growth
+$5.03M
Cap. Flow
+$40.7M
Cap. Flow %
14.41%
Top 10 Hldgs %
99.23%
Holding
21
New
4
Increased
7
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$30.7M
2
ALLO icon
Allogene Therapeutics
ALLO
+$10.6M
3
PASG icon
Passage Bio
PASG
+$2.68M
4
GHRS icon
GH Research
GHRS
+$2.35M
5
CRBU icon
Caribou Biosciences
CRBU
+$1.39M

Top Sells

Rank Stock Value
1
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$4.52M
2
CABA icon
Cabaletta Bio
CABA
+$3.68M
3
KRRO icon
Korro Bio
KRRO
+$129K
4
PVLA
Palvella Therapeutics
PVLA
+$88.6K
5
NEUP
Neuphoria Therapeutics
NEUP
+$33K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$89.6M 31.75%
1,793,866
+587,159
+49% +$30.7M
STOK icon
2
Stoke Therapeutics
STOK
$1.82B
$63.8M 22.59%
5,187,191
+2,000
+0% +$28.3K
CCCC icon
3
C4 Therapeutics
CCCC
$376M
$39.2M 13.9%
6,880,527
– –
GHRS icon
4
GH Research
GHRS
$1.87B
$28.1M 9.95%
4,195,894
+229,168
+6% +$2.35M
TCRX icon
5
TScan Therapeutics
TCRX
$51.9M
$26M 9.22%
5,224,600
– –
ALLO icon
6
Allogene Therapeutics
ALLO
$601M
$17.4M 6.15%
6,202,374
+3,974,079
+178% +$10.6M
CGEM icon
7
Cullinan Oncology
CGEM
$1.05B
$6.88M 2.44%
410,830
+33,507
+9% +$594K
PASG icon
8
Passage Bio
PASG
$15.9M
$5.9M 2.09%
421,348
+168,467
+67% +$2.68M
IBIO icon
9
iBio
IBIO
$71M
$1.91M 0.68%
862,279
+21,516
+3% +$42.5K
CRBU icon
10
Caribou Biosciences
CRBU
$156M
$1.33M 0.47%
+680,189
New +$1.39M
KOD icon
11
Kodiak Sciences
KOD
$2.59B
$708K 0.25%
+271,177
New +$721K
PVLA
12
Palvella Therapeutics
PVLA
$1.98B
$621K 0.22%
37,436
-6,063
-14% -$88.6K
CNTA
13
DELISTED
Centessa Pharmaceuticals
CNTA
$278K 0.1%
17,400
– –
NEUP
14
Neuphoria Therapeutics
NEUP
$19.7M
$241K 0.09%
45,806
-4,167
-8% -$33K
KNSA icon
15
Kiniksa Pharmaceuticals
KNSA
$4.83B
$206K 0.07%
8,231
-1,269
-13% -$30.9K
TENX icon
16
Tenax Therapeutics
TENX
$385M
$51K 0.02%
+14,751
New +$53.4K
IPSC icon
17
Century Therapeutics
IPSC
$381M
$32.5K 0.01%
+19,028
New +$37.3K
VYNE icon
18
VYNE Therapeutics
VYNE
$340K
$30.4K 0.01%
16,194
– –
CABA icon
19
Cabaletta Bio
CABA
$439M
– –
-492,103
Closed -$3.68M
KRRO icon
20
Korro Bio
KRRO
$153M
– –
-3,800
Closed -$129K
LBPH
21
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
– –
-167,317
Closed -$4.52M

Similar funds

SWM
SilverOak Wealth Management Edina, Minnesota $632M AUM 18.6% 1-Year Est. Return
RFA
Rollins Financial Advisors New York City, New York $632M AUM 23.84% 1-Year Est. Return
WA
WFM Asia Road Town, Tortola, British Virgin Islands $632M AUM 14.51% 1-Year Est. Return
AMM
American Money Management Rancho Santa Fe, California $632M AUM 14.06% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $634M AUM
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return

Lynx1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Lynx1 Capital Management held 21 positions worth $282M, up 1.8% from $277M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Lynx1 Capital Management deployed $40.7M of net new capital in Q3 2024, opening 4 new positions and adding to 7 existing holdings. Its largest new stake was Caribou Biosciences: 680,189 shares worth $1.33M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Palvella Therapeutics, an estimated $88.6K trimmed.

  • Lynx1 Capital Management's largest Q3 2024 buy was Caribou Biosciences: 680,189 shares worth $1.33M.
  • Lynx1 Capital Management added most to Merus in Q3 2024, an estimated $30.7M increase.
  • Lynx1 Capital Management's biggest Q3 2024 reduction was Palvella Therapeutics, cutting an estimated $88.6K.
  • Lynx1 Capital Management fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q3 2024, selling an estimated $4.52M.
  • Lynx1 Capital Management's ten largest holdings make up 99% of its $282M portfolio in Q3 2024.
  • Lynx1 Capital Management opened 4 new positions and closed 3 in Q3 2024.
  • Lynx1 Capital Management's portfolio value rose 1.8% quarter-over-quarter to $282M.

Based on Lynx1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.